Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Impact of Genes and the Environment on the Pathogenesis and Disease Course of Inflammatory Bowel Disease

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Pronounced Coronary Arteriosclerosis in Cirrhosis: Influence on Cardiac Function and Survival?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Microproteinuria Predicts Organ Failure in Patients Presenting with Acute Pancreatitis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Cerebral Blood Flow and Metabolism in Hepatic Encephalopathy-A Meta-Analysis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Impaired cerebral microcirculation induced by ammonium chloride in rats is due to cortical adenosine release

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Nyt navn og nye behandlinger for primær biliær kolangitis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Cumali Efe
  • Haider Al Taii
  • Henriette Ytting
  • Niklas Aehling
  • Rahima A Bhanji
  • Hannes Hagström
  • Tugrul Purnak
  • Luigi Muratori
  • Mårten Werner
  • Paolo Muratori
  • Daniel Klintman
  • Thomas D Schiano
  • Aldo J Montano-Loza
  • Thomas Berg
  • Fin Stolze Larsen
  • Naim Alkhouri
  • Ersan Ozaslan
  • Michael A Heneghan
  • Eric M Yoshida
  • Staffan Wahlin
Vis graf over relationer

BACKGROUND: We studied the efficacy and safety of mycophenolate mofetil (MMF) and tacrolimus as second-line therapy in pediatric patients with autoimmune hepatitis (AIH) who were intolerant or non-responders to standard therapy (corticosteroid and azathioprine).

PATIENTS AND METHODS: We performed a retrospective study of data from 13 centers in Europe, USA, and Canada. Thirty-eight patients (< 18 years old) who received second-line therapy (18 MMF and 20 tacrolimus), for a median of 72 months (range 8-182) were evaluated. Patients were categorized into two groups: Group 1 (n = 17) were intolerant to corticosteroid or azathioprine, and group 2 (n = 21) were non-responders to standard therapy.

RESULTS: Overall complete response rates were similar in patients treated with MMF and tacrolimus (55.6 vs. 65%, p = 0.552). In group 1, MMF and tacrolimus maintained a biochemical remission in 88.9 and 87.5% of patients, respectively (p = 0.929). More patients in group 2 given tacrolimus compared to MMF had a complete response, but the difference was not statistically significant (50.0 vs. 22.2%, p = 0.195). Biochemical remission was achieved in 71.1% (27/38) of patients by tacrolimus and/or MMF. Decompensated cirrhosis was more commonly seen in MMF and/or tacrolimus non-responders than in responders (45.5 vs. 7.4%, p = 0.006). Five patients who received second-line therapy (2 MMF and 3 tacrolimus) developed side effects that led to therapy withdrawal.

CONCLUSIONS: Long-term therapy with MMF or tacrolimus was generally well tolerated by pediatric patients with AIH. Both MMF and tacrolimus had excellent efficacy in patients intolerant to corticosteroid or azathioprine. Tacrolimus might be more effective than MMF in patients failing previous therapy.

OriginalsprogEngelsk
TidsskriftDigestive Diseases and Sciences
Vol/bind63
Udgave nummer5
Sider (fra-til)1348-1354
Antal sider7
ISSN0002-9211
DOI
StatusUdgivet - maj 2018

ID: 56500853